These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1899619)

  • 1. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.
    Mikkelsen J; Thomsen J; Ezban M
    Biochemistry; 1991 Feb; 30(6):1533-7. PubMed ID: 1899619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid residues 721-729 are required for full factor VIII activity.
    Kjalke M; Heding A; Talbo G; Persson E; Thomsen J; Ezban M
    Eur J Biochem; 1995 Dec; 234(3):773-9. PubMed ID: 8575434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
    Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and characterization of a mutant recombinant blood coagulation factor VIII (rFVIII (m)).
    Oh SH; Cho SY; Jin HS; Jeong DL; Jung SG; Oh KH
    Exp Mol Med; 2002 Jul; 34(3):233-8. PubMed ID: 12216115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.
    Kannicht C; Ramström M; Kohla G; Tiemeyer M; Casademunt E; Walter O; Sandberg H
    Thromb Res; 2013 Jan; 131(1):78-88. PubMed ID: 23058466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII.
    Pittman DD; Wang JH; Kaufman RJ
    Biochemistry; 1992 Apr; 31(13):3315-25. PubMed ID: 1554716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and characterization of a codon-optimized blood coagulation factor VIII.
    Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
    J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
    Ezban M; Vad K; Kjalke M
    Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction.
    Kolind MP; Nørby PL; Berchtold MW; Johnsen LB
    J Biotechnol; 2011 Feb; 151(4):357-62. PubMed ID: 21219947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII.
    Meulien P; Faure T; Mischler F; Harrer H; Ulrich P; Bouderbala B; Dott K; Sainte Marie M; Mazurier C; Wiesel ML
    Protein Eng; 1988 Oct; 2(4):301-6. PubMed ID: 3150544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage.
    Michnick DA; Pittman DD; Wise RJ; Kaufman RJ
    J Biol Chem; 1994 Aug; 269(31):20095-102. PubMed ID: 8051097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
    Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
    Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
    O'Sullivan JM; Jenkins PV; Rawley O; Gegenbauer K; Chion A; Lavin M; Byrne B; O'Kennedy R; Preston RJ; Brophy TM; O'Donnell JS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):855-63. PubMed ID: 27013611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.
    Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M
    Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII.
    Oh SH; Lee MY; Song DW
    Exp Mol Med; 1999 Jun; 31(2):95-100. PubMed ID: 10410309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
    Mannully ST; L N R; Pulicherla KK
    Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tyrosine sulfate residues in antihemophilic recombinant factor VIII by liquid chromatography electrospray ionization tandem mass spectrometry and amino acid analysis.
    Severs JC; Carnine M; Eguizabal H; Mock KK
    Rapid Commun Mass Spectrom; 1999; 13(11):1016-23. PubMed ID: 10368977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a plasma- and albumin-free recombinant von Willebrand factor.
    Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity.
    Pittman DD; Tomkinson KN; Michnick D; Selighsohn U; Kaufman RJ
    Biochemistry; 1994 Jun; 33(22):6952-9. PubMed ID: 8204629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.